Sangamo Therapeutics, Inc. (SGMOQ)
OTCMKTS · Delayed Price · Currency is USD
0.0450
+0.0060 (15.38%)
At close: Jun 26, 2026
Sangamo Therapeutics Stock Forecast
OTC-SGMOQ's stock price has decreased by -92.27% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 2 analysts polled by S&P Global, Sangamo Therapeutics stock has a consensus rating of "Buy" and an average price target of $1.50. The average 1-year stock price forecast is 3,233.33% higher than the current stock price, while the lowest is $1.00 (+2,122.22%) and the highest is $2.00 (+4,344.44%).
Price Target: $1.50 (+3,233.33%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Sangamo Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 2 |
Financial Forecast
Revenue This Year
9.90M
from 39.55M
Decreased by -74.97%
Revenue Next Year
70.80M
from 9.90M
Increased by 615.15%
EPS This Year
-0.30
from -0.39
EPS Next Year
-0.10
from -0.30
EPS and Forward PE are based on non-GAAP adjusted numbers.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 9.9M | ||
| Avg | 9.9M | ||
| Low | 9.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -75.0% | ||
| Avg | -75.0% | ||
| Low | -75.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.30 | ||
| Avg | -0.30 | ||
| Low | -0.30 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |